The lung microbiome in end-stage Lymphangioleiomyomatosis.

ABSTRACT: Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease.

SUBMITTER: Ng J 

PROVIDER: S-EPMC8549264 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature